Melasma NT Cream (Niacinamide / Tranexamic Acid) (30 mL)

Melasma NT Cream is a topical formulation commonly used to treat melasma and other forms of hyperpigmentation. It typically contains a combination of active ingredients such as hydroquinone (a skin-lightening agent), tretinoin (a retinoid), and a mild corticosteroid like mometasone.

Mechanisms of Action:
The cream works through a synergistic effect of its ingredients. Hydroquinone inhibits the enzyme tyrosinase, which is essential for melanin production, thereby lightening pigmented areas. Tretinoin increases skin cell turnover and enhances the absorption of hydroquinone. The corticosteroid component helps reduce inflammation and skin irritation that may result from the use of the other active agents.

Contraindications & Precautions:
Melasma NT Cream should not be used in individuals who are allergic to any of its ingredients. It is also contraindicated in those with active skin infections, broken or inflamed skin, or conditions such as eczema in the treatment area. Caution is advised when using the cream on sensitive skin, and prolonged use should be avoided to prevent side effects like skin thinning. Sun exposure should be minimized, and broad-spectrum sunscreen should be used during treatment.

Adverse Reactions / Side Effects:
Common side effects include mild burning, stinging, redness, dryness, and peeling at the application site. Rarely, allergic reactions may occur and require discontinuation of the cream.

Pregnancy & Breastfeeding:
Melasma NT Cream should be used with caution during pregnancy and only if clearly indicated, especially avoiding use during the first trimester. During breastfeeding, it is advisable not to apply the cream on or near the chest area to prevent exposure to the infant. As with any medication during pregnancy or lactation, the benefits and risks should be carefully weighed under medical supervision.

Store this medication in its original container at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

1. Niaspan (niacin extended-release) tablet package insert. North Chicago, IL: Abbott Laboratories; 2015 Apr.
2. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-12.
3. Taylor AJ, Villines TC, Stanck EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009. Epub ahead of print, doi:10.1056/NEJMoa907569.
4. Lee JMS, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: A randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009;54:1787—94.
5. McKenney JM, et al. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7.
6. Lysteda (tranexamic acid) package insert. Parsippany, NJ: Ferring Pharmaceuticals Inc.; 2016 Mar.
7. Tranexamic acid in sodium chloride injection package insert. Lenoir, NC: Exela Pharma Sciences, LLC; 2019 Apr.
8. Colletti RB, Neufeld EJ, Roff NK, et al. Niacin treatment of hypercholesterolemia in children. Pediatrics 1993;92:78-82.
9. Expert Panel: National Cholesterol Education Program. Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 1992;89(suppl 2):525-84.
10. Niacinamide. In: Drugs in Pregnancy and Lactation. A Reference Guide to Fetal and Neonatal Risk. Briggs GG, Freeman RK, Yaffe SJ, (eds.) 7th ed., Philadelphia PA: Lippincott Williams and Wilkins; 2005:1140-1
11. Health Care Financing Administration. Interpretive Guidelines for Long-term Care Facilities. Title 42 CFR 483.25(l) F329: Unnecessary Drugs. Revised 2015.
12. Cyklokapron (tranexamic acid) package insert. New York, NY: Pfizer Injectables; 2017 Nov.
13. Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012;129:308-20.
14. Niaspan (niacin extended release) tablet package insert. North Chicago, IL: Abbott Laboratories; 2015 Apr.
15. Niacor (Niacin tablets) package insert. Minneapolis, MN: Upsher-Smith Laboratories, Inc.; 2000 Feb.